Safest Maximum Testosterone Dose for Transgender Males
For transgender males without contraindications, the safest maximum testosterone dose is 100 mg intramuscular weekly (or 200 mg every 2 weeks), targeting serum testosterone levels of 450–600 ng/dL in the mid-normal male range. 1, 2
Recommended Dosing Regimens
Standard Intramuscular Protocols
- Testosterone cypionate or enanthate 100 mg intramuscular weekly is the most commonly used regimen, providing stable serum levels and minimizing the "roller-coaster" effect seen with less frequent dosing. 2, 3
- Alternatively, 200 mg intramuscular every 2 weeks is acceptable but produces greater serum testosterone variability, with supraphysiologic peaks 2–5 days post-injection and return to baseline by days 10–14. 2, 4
- Subcutaneous administration of testosterone cypionate 100 mg weekly is an effective and safe alternative that is relatively painless, easy to self-inject, and produces stable therapeutic levels between injections (mean 627 ± 206 ng/dL). 4
Transdermal Options
- Testosterone gel 1.62% at 40.5–81 mg daily applied to upper arms and shoulders provides more stable day-to-day testosterone levels and carries a lower risk of erythrocytosis (≈15%) compared with injectable preparations (≈44%). 2, 5
- The gel should be applied to clean, dry skin between 8–10 AM, allowed to dry for 2 hours before swimming or showering, and the application site must be covered with clothing to prevent secondary exposure to others. 5
Low-Dose Considerations
- Low-dose testosterone (≤62.5 mg/week intramuscular) is sufficient to achieve menstrual cessation and increase lean body mass in transgender men, though higher doses produce earlier and greater muscle mass gains during the first year. 6
- Both low-dose and standard-dose regimens show similar long-term safety profiles without dose-dependent increases in polycythemia or dyslipidemia. 6
Target Testosterone Levels
- Aim for serum total testosterone concentrations of 450–600 ng/dL (mid-normal male range) when measured at the midpoint between injections (days 5–7 for weekly dosing, days 7–10 for bi-weekly dosing). 1, 2
- For injectable testosterone, measure levels midway between injections—not at the peak (days 2–5) or trough (days 13–14)—to accurately reflect average exposure and guide dose adjustments. 2
- For transdermal testosterone, levels can be measured at any time after 2–3 months of stable therapy. 2
Monitoring Requirements
Initial Phase (First Year)
- First follow-up at 2–3 months: measure total testosterone (midway between injections for IM), hematocrit/hemoglobin, and assess clinical response (menstrual cessation, virilization, mood improvement). 2, 3
- Every 3 months during the first year: repeat testosterone levels, hematocrit, and clinical assessment to ensure therapeutic adequacy and safety. 3
Long-Term Monitoring
- Every 6–12 months after the first year: measure testosterone, hematocrit, lipid profile (total cholesterol, triglycerides, HDL), blood pressure, and fasting glucose/HbA1c. 2, 3
- Hematocrit must be checked at every visit—withhold testosterone if hematocrit exceeds 54% and consider therapeutic phlebotomy in high-risk cases. 2
Expected Timeline of Physical Changes
- Menstrual cessation typically occurs within 2–6 months of starting therapy, with cumulative cessation rates up to 12 months not significantly different between low-dose and standard-dose regimens. 6
- Facial and body hair, voice deepening, clitoral enlargement, and increased lean body mass begin within several months and continue to develop over 1–3 years. 7, 8
- Maximum virilization effects are usually achieved after 3–5 years of regular testosterone use. 3
- Lean body mass increases most rapidly during the first year, with higher doses producing earlier gains, followed by a slight increase in both lean mass and body fat percentage over the long term. 6
Safety Considerations and Adverse Effects
Common Adverse Effects
- Acne, male-pattern alopecia, increased hematocrit, reduced HDL cholesterol, increased triglycerides, and possible increases in systolic blood pressure are expected with testosterone therapy. 7, 8
- Erythrocytosis develops in approximately 43.8% of patients on intramuscular testosterone versus 15.4% on transdermal preparations, making transdermal formulations preferable for patients at higher risk. 2
Absolute Contraindications
- Active or treated breast cancer (though testosterone therapy with or without mastectomy reduces breast cancer risk in transgender men). 7
- Hematocrit >54% at baseline or during therapy. 2
- Pregnancy or desire for future fertility without fertility preservation counseling, as testosterone suppresses ovulation and may reduce fertility potential. 2, 8
Cardiovascular Safety
- The 2023 TRAVERSE trial (5,246 men, mean follow-up 21.7 months) found no significant increase in major adverse cardiac events or non-fatal stroke with transdermal testosterone gel compared with placebo in men with pre-existing or high cardiovascular risk. 2
- Elevated hematocrit increases blood viscosity, which can exacerbate coronary, cerebrovascular, and peripheral arterial disease, particularly in older adults or those with pre-existing cardiovascular disease. 2
Formulation Selection Algorithm
First-Line: Intramuscular Testosterone
- Testosterone cypionate or enanthate 100 mg IM weekly is the most cost-effective option (≈$156/year) with proven efficacy and safety. 2
- Subcutaneous administration may be preferred for patients who wish to self-inject, as it is relatively painless and produces stable therapeutic levels. 4
Alternative: Transdermal Testosterone
- Testosterone gel 1.62% at 40.5–81 mg daily is preferred for patients at higher risk of erythrocytosis or those who prefer daily application over injections, despite higher cost (≈$2,135/year). 2, 5
- Strict adherence to application precautions is mandatory to prevent secondary exposure to children and women, including washing hands immediately after application, covering the site with clothing, and washing the site thoroughly before anticipated skin-to-skin contact. 5
Low-Dose Option
- Testosterone cypionate or enanthate ≤62.5 mg IM weekly is sufficient for patients who prioritize menstrual cessation and gradual masculinization over rapid muscle mass gains, with similar long-term safety. 6
Critical Pitfalls to Avoid
- Do not exceed 200 mg IM every 2 weeks (or 100 mg weekly) without documented subtherapeutic levels at midpoint testing, as higher doses increase erythrocytosis risk without additional clinical benefit. 2
- Do not measure testosterone at the peak (days 2–5) or trough (days 13–14) after injection, as this will produce misleading results and inappropriate dose adjustments. 2
- Do not ignore hematocrit elevations of 50–52% in patients with cardiovascular risk factors, as even modest increases raise blood viscosity and thrombotic risk. 2
- Do not continue full-dose testosterone when hematocrit exceeds 54%—this is an absolute indication to withhold therapy and consider dose reduction or formulation switch. 2
- Do not prescribe testosterone without counseling about fertility preservation options, as testosterone suppresses ovulation and may reduce future fertility potential. 8
Expected Clinical Outcomes
- Desired effects include increased facial and body hair, increased lean mass and strength, decreased fat mass, voice deepening, increased sexual desire, menstrual cessation, clitoral enlargement, and reductions in gender dysphoria, perceived stress, anxiety, and depression. 7
- Quality of life improvements are well-documented, with testosterone therapy being generally well-tolerated and safe with appropriate endocrine guidance and monitoring. 8
- Long-term GAHT for transgender men is safe and effective, with no long-term dose-dependent side effects such as polycythemia or dyslipidemia when testosterone levels are maintained within male physiological ranges (300–1,000 ng/dL). 3, 6